Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

MUROMONAB-CD3 for Allogenic stem cell transplantation: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 5 adverse event reports in the FDA FAERS database where MUROMONAB-CD3 was used for Allogenic stem cell transplantation.

Most Reported Side Effects for MUROMONAB-CD3

Side Effect Reports % Deaths Hosp.
Post transplant lymphoproliferative disorder 22 19.3% 3 14
Infection 16 14.0% 6 3
Cytomegalovirus infection 13 11.4% 5 4
Cytomegalovirus oesophagitis 10 8.8% 1 0
Drug resistance 10 8.8% 1 0
Duodenitis 10 8.8% 1 1
Gastritis 10 8.8% 1 1
Weight decreased 10 8.8% 1 0
Chest pain 9 7.9% 1 0
Cytomegalovirus chorioretinitis 9 7.9% 0 0
Cytomegalovirus infection reactivation 9 7.9% 1 0
Encephalitis 9 7.9% 1 0
Gastric fistula 9 7.9% 1 0
Gastric ulcer 9 7.9% 1 0
Gastrointestinal ulcer 9 7.9% 1 0

Other Indications for MUROMONAB-CD3

Immunosuppressant drug therapy (38) Prophylaxis against transplant rejection (20) Prophylaxis against graft versus host disease (13) Immunosuppression (12) Transplant rejection (12) Product used for unknown indication (11) Bone marrow conditioning regimen (8)

Other Drugs Used for Allogenic stem cell transplantation

FLUDARABINE (2,008) BUSULFAN (1,624) THIOTEPA (1,476) CYCLOPHOSPHAMIDE (701) CYCLOSPORINE (556) LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN (539) MYCOPHENOLATE MOFETIL (428) TREOSULFAN (397) MELPHALAN (374) TACROLIMUS (326)

Related Pages

MUROMONAB-CD3 Full Profile All Allogenic stem cell transplantation Drugs MUROMONAB-CD3 Demographics MUROMONAB-CD3 Timeline